vs
Side-by-side financial comparison of Clearwater Analytics Holdings, Inc. (CWAN) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
Clearwater Analytics Holdings, Inc. is the larger business by last-quarter revenue ($217.5M vs $168.4M, roughly 1.3× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 72.0%). Over the past eight quarters, Clearwater Analytics Holdings, Inc.'s revenue compounded faster (45.5% CAGR vs 10.6%).
Clearwater Analytics Holdings, Inc. is an American software-as-a-service (SaaS) fintech company that provides automated investment accounting, performance, compliance, and risk reporting worldwide. Clearwater is a publicly traded company headquartered in Boise, Idaho, with additional offices in London, Edinburgh, New York City and Noida.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
CWAN vs ESPR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $217.5M | $168.4M |
| Net Profit | $-11.8M | — |
| Gross Margin | 67.2% | — |
| Operating Margin | -3.1% | 50.6% |
| Net Margin | -5.4% | — |
| Revenue YoY | 72.0% | 143.7% |
| Net Profit YoY | -102.8% | — |
| EPS (diluted) | $-0.04 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $217.5M | $168.4M | ||
| Q3 25 | $205.1M | $87.3M | ||
| Q2 25 | $181.9M | $82.4M | ||
| Q1 25 | $126.9M | $65.0M | ||
| Q4 24 | $126.5M | $69.1M | ||
| Q3 24 | $115.8M | $51.6M | ||
| Q2 24 | $106.8M | $73.8M | ||
| Q1 24 | $102.7M | $137.7M |
| Q4 25 | $-11.8M | — | ||
| Q3 25 | $-10.3M | $-31.3M | ||
| Q2 25 | $-23.2M | $-12.7M | ||
| Q1 25 | $6.5M | $-40.5M | ||
| Q4 24 | $419.3M | — | ||
| Q3 24 | $3.6M | $-29.5M | ||
| Q2 24 | $-430.0K | $-61.9M | ||
| Q1 24 | $1.9M | $61.0M |
| Q4 25 | 67.2% | — | ||
| Q3 25 | 65.6% | — | ||
| Q2 25 | 65.1% | — | ||
| Q1 25 | 73.3% | — | ||
| Q4 24 | 73.5% | — | ||
| Q3 24 | 72.9% | — | ||
| Q2 24 | 72.0% | — | ||
| Q1 24 | 72.6% | — |
| Q4 25 | -3.1% | 50.6% | ||
| Q3 25 | 3.2% | -11.4% | ||
| Q2 25 | -8.0% | 8.6% | ||
| Q1 25 | 5.6% | -34.0% | ||
| Q4 24 | 1.0% | -6.4% | ||
| Q3 24 | 6.3% | -31.0% | ||
| Q2 24 | 3.6% | 3.5% | ||
| Q1 24 | -0.2% | 52.5% |
| Q4 25 | -5.4% | — | ||
| Q3 25 | -5.0% | -35.9% | ||
| Q2 25 | -12.8% | -15.4% | ||
| Q1 25 | 5.1% | -62.2% | ||
| Q4 24 | 331.5% | — | ||
| Q3 24 | 3.1% | -57.2% | ||
| Q2 24 | -0.4% | -83.9% | ||
| Q1 24 | 1.8% | 44.3% |
| Q4 25 | $-0.04 | $0.32 | ||
| Q3 25 | $-0.04 | $-0.16 | ||
| Q2 25 | $-0.09 | $-0.06 | ||
| Q1 25 | $0.03 | $-0.21 | ||
| Q4 24 | $1.65 | $-0.14 | ||
| Q3 24 | $0.02 | $-0.15 | ||
| Q2 24 | $0.00 | $-0.33 | ||
| Q1 24 | $0.01 | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $91.2M | $167.9M |
| Total DebtLower is stronger | $822.6M | — |
| Stockholders' EquityBook value | $2.0B | $-302.0M |
| Total Assets | $3.0B | $465.9M |
| Debt / EquityLower = less leverage | 0.41× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $91.2M | $167.9M | ||
| Q3 25 | $64.1M | $92.4M | ||
| Q2 25 | $71.9M | $86.1M | ||
| Q1 25 | $282.9M | $114.6M | ||
| Q4 24 | $255.5M | $144.8M | ||
| Q3 24 | $305.8M | $144.7M | ||
| Q2 24 | $257.9M | $189.3M | ||
| Q1 24 | $267.6M | $226.6M |
| Q4 25 | $822.6M | — | ||
| Q3 25 | $838.9M | — | ||
| Q2 25 | $878.1M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $43.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $2.0B | $-302.0M | ||
| Q3 25 | $2.0B | $-451.4M | ||
| Q2 25 | $2.0B | $-433.5M | ||
| Q1 25 | $1.1B | $-426.2M | ||
| Q4 24 | $1.0B | $-388.7M | ||
| Q3 24 | $403.2M | $-370.2M | ||
| Q2 24 | $380.6M | $-344.2M | ||
| Q1 24 | $406.2M | $-294.3M |
| Q4 25 | $3.0B | $465.9M | ||
| Q3 25 | $3.0B | $364.0M | ||
| Q2 25 | $3.0B | $347.1M | ||
| Q1 25 | $1.3B | $324.0M | ||
| Q4 24 | $1.2B | $343.8M | ||
| Q3 24 | $623.5M | $314.1M | ||
| Q2 24 | $585.1M | $352.3M | ||
| Q1 24 | $547.8M | $373.1M |
| Q4 25 | 0.41× | — | ||
| Q3 25 | 0.42× | — | ||
| Q2 25 | 0.45× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.04× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $55.3M | $45.2M |
| Free Cash FlowOCF − Capex | $52.3M | — |
| FCF MarginFCF / Revenue | 24.0% | — |
| Capex IntensityCapex / Revenue | 1.4% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $164.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $55.3M | $45.2M | ||
| Q3 25 | $49.0M | $-4.3M | ||
| Q2 25 | $47.1M | $-31.4M | ||
| Q1 25 | $24.5M | $-22.6M | ||
| Q4 24 | $-29.2M | $-35.0M | ||
| Q3 24 | $49.6M | $-35.3M | ||
| Q2 24 | $43.9M | $-7.2M | ||
| Q1 24 | $10.0M | $53.8M |
| Q4 25 | $52.3M | — | ||
| Q3 25 | $44.9M | — | ||
| Q2 25 | $44.1M | — | ||
| Q1 25 | $23.0M | — | ||
| Q4 24 | $-30.0M | — | ||
| Q3 24 | $48.1M | $-35.5M | ||
| Q2 24 | $42.4M | $-7.3M | ||
| Q1 24 | $8.6M | $53.8M |
| Q4 25 | 24.0% | — | ||
| Q3 25 | 21.9% | — | ||
| Q2 25 | 24.2% | — | ||
| Q1 25 | 18.2% | — | ||
| Q4 24 | -23.7% | — | ||
| Q3 24 | 41.5% | -68.7% | ||
| Q2 24 | 39.7% | -9.9% | ||
| Q1 24 | 8.4% | 39.0% |
| Q4 25 | 1.4% | 0.0% | ||
| Q3 25 | 2.0% | 0.0% | ||
| Q2 25 | 1.6% | 0.0% | ||
| Q1 25 | 1.2% | 0.0% | ||
| Q4 24 | 0.6% | 0.0% | ||
| Q3 24 | 1.3% | 0.3% | ||
| Q2 24 | 1.4% | 0.1% | ||
| Q1 24 | 1.4% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.76× | — | ||
| Q4 24 | -0.07× | — | ||
| Q3 24 | 13.66× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 5.29× | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CWAN
Segment breakdown not available.
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
